Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
The vesicular stomatitis virus cytopathic effect reduction assay is suitable to quantify polyethylene glycol-alpha interferon 2a (PEG-IFN-alpha 2a) and PEG-IFN-alpha 2b. Human serum and ribavirin did not interfere with the assay. This bioassay was successfully used for assaying PEG-IFN-alpha 2a and PEG-IFN-alpha 2b in serum samples from patients undergoing combination therapy.
Laboratoire de Virologie EA 2046-IFR 30, CHU PURPAN, Place du Dr Baylac, TSA 40031, 31059 Toulouse Cedex 9, France. aboulestin@yahoo.fr
Anne
A
Boulestin
Nassim
N
Kamar
Florence
F
Legrand-Abravanel
Karine
K
Sandres-Saune
Laurent
L
Alric
Jean-Pierre
JP
Vinel
Lionel
L
Rostaing
Jacques
J
Izopet
D000818:Animals; D000998:Antiviral Agents / Q000097:blood* / Q000627:therapeutic use; D001681:Biological Assay; D002417:Cattle; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000097:blood* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000494:pharmacology; D014721:Vesicular stomatitis Indiana virus / Q000187:drug effects
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a